search
Back to results

Prospective Single Center Open Label Study of Shoulder OA Pain

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Durolane
Sponsored by
Bioventus LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis focused on measuring degenerative arthritis

Eligibility Criteria

19 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of glenohumeral osteoarthritis
  • SPOM score greater than or equal to 50 in study shoulder
  • Willing to discontinue oral and topical analgesia other than rescue acetaminophen
  • abstinence from any other IA or per-articular injections for the shoulder during the course of the trial
  • patients with chronic shoulder pain lasting more than 6 months without clinically significant improvement in pain over the past one month
  • pain at least 50% of the days during previous month
  • patients who have failed conventional therapy of NSAIDs or steroid injections
  • patients with a retained active range of motion of at least 30% in all directions to rule out frozen shoulder
  • cooperative and able to communicate effectively
  • agree not to participate in any other studies during trial

Exclusion Criteria:

  • significant pain from other joints requiring chronic analgesic therapy
  • presence of one or more conditions besides OA that could confound pain and functional assessments
  • clinically apparent tense effusion, malalignment or instability in study shoulder
  • shoulder x-rays of acute fractures, sever loss of bone density, avascular necrosis or severe deformity
  • inability to abstain from analgesic use other than rescue acetaminophen
  • IA injections of steroids to the study shoulder within 3 months or any other joint within the prior month
  • IA injection of hyaluronic acid in the study shoulder within 9 months of baseline
  • allergic reaction to HA
  • any medical condition which in the opinion of the investigator makes the patient unsuitable for inclusion or may compromise pain assessments of shoulder
  • uncontrolled hypothyroidism
  • pregnant or breastfeeding women
  • planned surgical procedure
  • history or presence of septic arthritis of study joint or active skin disease or infection in the area of the injection site
  • treatment with glucosamine/chondroitin initiated or unstable within 3 months of baseline or change in physical therapy for the study shoulder within 1 month of baseline

Sites / Locations

  • St. Michaels Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Durolane 3ml

Arm Description

Single intra-articular injection into shoulder

Outcomes

Primary Outcome Measures

Shoulder pain on movement (SPOM) 0-100mm VAS

Secondary Outcome Measures

Shoulder pain at night (SPAN) 0-100mm VAS
American Shoulder and Elbow Surgeons (ASES) Standardized Shoulder Assessment form
Patient Global Assessment (PGA)
Shoulder pain rescue medication diary
Adverse events, concomitant medications, physical exam

Full Information

First Posted
November 18, 2015
Last Updated
February 12, 2021
Sponsor
Bioventus LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT02610504
Brief Title
Prospective Single Center Open Label Study of Shoulder OA Pain
Official Title
A 26 Week Prospective Open Label Clinical Study Evaluating A Single Intra-Articular Injection of Durolane 3ml for Treatment of Osteoarthritis Pain of the Shoulder
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
April 8, 2015 (Actual)
Primary Completion Date
May 23, 2017 (Actual)
Study Completion Date
May 23, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bioventus LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Open label, prospective, single cohort study of Durolane 3ml intra-articular injection into the shoulder for pain in mild to moderate patients
Detailed Description
Subjects 19-85 years old will receive a single intra-articular (IA) injection of DUROLANE® 3mL given for the relief of pain in the treatment of symptomatic osteoarthritis (OA) of the shoulder followed over a 26-week time period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
degenerative arthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
41 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Durolane 3ml
Arm Type
Experimental
Arm Description
Single intra-articular injection into shoulder
Intervention Type
Device
Intervention Name(s)
Durolane
Other Intervention Name(s)
Hyaluronic Acid
Intervention Description
single injection of 3ml
Primary Outcome Measure Information:
Title
Shoulder pain on movement (SPOM) 0-100mm VAS
Time Frame
over 26 weeks
Secondary Outcome Measure Information:
Title
Shoulder pain at night (SPAN) 0-100mm VAS
Time Frame
over 26 weeks
Title
American Shoulder and Elbow Surgeons (ASES) Standardized Shoulder Assessment form
Time Frame
over 26 weeks
Title
Patient Global Assessment (PGA)
Time Frame
over 26 weeks
Title
Shoulder pain rescue medication diary
Time Frame
over 26 weeks
Title
Adverse events, concomitant medications, physical exam
Time Frame
over 26 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of glenohumeral osteoarthritis SPOM score greater than or equal to 50 in study shoulder Willing to discontinue oral and topical analgesia other than rescue acetaminophen abstinence from any other IA or per-articular injections for the shoulder during the course of the trial patients with chronic shoulder pain lasting more than 6 months without clinically significant improvement in pain over the past one month pain at least 50% of the days during previous month patients who have failed conventional therapy of NSAIDs or steroid injections patients with a retained active range of motion of at least 30% in all directions to rule out frozen shoulder cooperative and able to communicate effectively agree not to participate in any other studies during trial Exclusion Criteria: significant pain from other joints requiring chronic analgesic therapy presence of one or more conditions besides OA that could confound pain and functional assessments clinically apparent tense effusion, malalignment or instability in study shoulder shoulder x-rays of acute fractures, sever loss of bone density, avascular necrosis or severe deformity inability to abstain from analgesic use other than rescue acetaminophen IA injections of steroids to the study shoulder within 3 months or any other joint within the prior month IA injection of hyaluronic acid in the study shoulder within 9 months of baseline allergic reaction to HA any medical condition which in the opinion of the investigator makes the patient unsuitable for inclusion or may compromise pain assessments of shoulder uncontrolled hypothyroidism pregnant or breastfeeding women planned surgical procedure history or presence of septic arthritis of study joint or active skin disease or infection in the area of the injection site treatment with glucosamine/chondroitin initiated or unstable within 3 months of baseline or change in physical therapy for the study shoulder within 1 month of baseline
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael McKee, MD
Organizational Affiliation
St. Michaels Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Michaels Hospital
City
Toronto
State/Province
Ontario
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Prospective Single Center Open Label Study of Shoulder OA Pain

We'll reach out to this number within 24 hrs